Isotoxic stereotactic reirradiation for recurrent pelvic cancers

Pagett, CJH; Lilley, J; O'Hara, C; Appelt, A; Murray, L; Bokrantz, R; Ödén, J; Svensson, S; Harrison, M; Camilleri, P; Muirhead, R; Robinson, M; Thompson, C

Journal article

Isotoxic stereotactic reirradiation for recurrent pelvic cancers

Abstract:: Background and purposeReirradiation is clinically challenging, requiring a balance between delivery of dose to tumour while respecting cumulative organ at risk (OAR) dose constraints. Standard prescriptions are often conservative, ignoring patient variability in achievable OAR doses. Isotoxic radiotherapy individualises treatment by delivering the highest equieffective dose in 2 Gy per fraction (EQD2Gy) while meeting OAR constraints. This technical feasibility study assessed isotoxic pelvic reirradiation using cumulative OAR constraints, the original dose distribution as background, and voxel-by-voxel EQD2Gy optimisation.Materials and methodsData from 30 patients previously treated with pelvic stereotactic body radiotherapy (SBRT) at three UK centres were included. OARs were delineated on both previous and reirradiation image sets and deformably registered. Previous dose was mapped to the current image set and used as background dose for SBRT planning, following published methods. Initial 25 Gy in five fractions (25 Gy/5#) plans were generated for all patients, with further isotoxic dose escalation conducted up to a maximum of 50 Gy (fraction number fixed) until cumulative EQD2Gy constraints were reached.ResultsFor 25 of 30 patients, clinically acceptable isotoxic plans were obtained, with 23 exceeding the standard UK reirradiation prescription dose of 30 Gy/5#. The median isotoxic prescription was 42 Gy/5#, with four patient plans reaching the upper evaluated limit of 50 Gy. Vessels and the sacral plexus were most frequently dose limiting.ConclusionThis study highlighted the feasibility of isotoxic pelvic reirradiation and supports further investigation into automation and prediction models to streamline implementation in clinical practice.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Pagett, C. J. H., Lilley, J., O'Hara, C., Appelt, A., Murray, L., Bokrantz, R., Ödén, J., Svensson, S., Harrison, M., Camilleri, P., Muirhead, R., Robinson, M., & Thompson, C. (2025). Isotoxic stereotactic reirradiation for recurrent pelvic cancers. Physics and Imaging in Radiation Oncology, 37, 100889.

MLA Style

Pagett, CJH, et al. “Isotoxic Stereotactic Reirradiation for Recurrent Pelvic Cancers.” Physics and Imaging in Radiation Oncology, vol. 37, 2025, p. 100889.

Chicago Style

Pagett, CJH, J Lilley, C O'Hara, et al. 2025. “Isotoxic Stereotactic Reirradiation for Recurrent Pelvic Cancers.” Physics and Imaging in Radiation Oncology 37: 100889.
Print